<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222013</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571ABR22T</org_study_id>
    <nct_id>NCT01222013</nct_id>
  </id_info>
  <brief_title>Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)</brief_title>
  <official_title>Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renato Melaragno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, through molecular response and
      event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM
      &quot;like&quot; Induction in children with ALL Ph+.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study was suspended before recruitment, due to logistic issues.
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy, through molecular response and event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM &quot;like&quot; Induction in children with ALL Ph+.</measure>
    <time_frame>Up to 24 months.</time_frame>
    <description>Cytogenetic and molecular response will be evaluate at the end of Induction I (D33), before each consolidation block (HR 1, 2 and 3), before re-induction, before maintenanceand at the end of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate toxicity and tolerability in the administration of Imatinib in conjunction with chemotherapy in children with ALL Ph+.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Toxicity and tolerability will be verified in every visit according through:
Adverse events during the study.
Laboratory exams.
Vital signs and body weight.
Physical evaluation.
Concomitant medication.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)</condition>
  <arm_group>
    <arm_group_label>Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.</description>
    <arm_group_label>Imatinib Mesylate</arm_group_label>
    <other_name>Glivec, MI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnose: therapy-naïve ALL, except for patients that performed Induction for ALL (33
             days) exactly as this protocol and; documented Ph+, to be confirmed by conventional
             cytogenetic - t(9;22) (q34;q11) or FISH and/or gene BCR-ABL presence by RT-PCR or
             FISH.

          2. Female patients of childbearing age, should have pregnancy test (blood βhCG) performed
             before treatment initiation. Effective contraception must be used during treatment.
             Pregnant women won't be included.

          3. Life expectation &gt; 8 weeks.

          4. Medications: antineoplastic treatment-naïve, including corticotherapy, except for
             patients that performed Induction for ALL (33 days) exactly as this protocol.

          5. Signed ICF by child legal responsible.

          6. Laboratory: renal function (serum creatinine ≤ 1,5 x ULN and/or Clearance ≥70
             ml/min/1,73m2), hepatic function (total bilirubin ≤ 1,5 x ULN, TGP/TGO &lt; 10 x ULN and
             albumin &gt; 2 g/dl.

        Exclusion Criteria:

          1. Any inclusion criteria missing.

          2. Pregnant patient or breastfeeding.

          3. Patient considered incapable to follow purposed treatment.

          4. Subject with infectious process, in activity, grade IV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Renato Melaragno</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

